Tag Archives: Biopharma

AbbVie, Amgen, and Roche Most Exposed to Biosimilar Competition

While biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, according to a new report on the global biosimilar drugs market.
Posted in Biotech, Gene therapy | Also tagged , , , | Leave a comment

The Affordable Healthcare Act's Effect of Biopharma Innovation

The Affordable Care Act (ACA) has sent biopharmaceutical companies scrambling to understand how their business model, including its ability to innovate, will change as healthcare reform moves forward. Within this uncertain market, what is obvious is that the industry is in the midst of significant transition. Critical drivers of this change are largely macroeconomic; policy […]
Posted in Biotech, Regulatory | Also tagged , , | Leave a comment

Biopharma's High Performers 2014

Accenture has launched the latest version of its annual study of the biopharmaceutical industry. The High Performance Business (HPB) report analyses  the long-term performance of the 16 largest pharma companies globally, highlighting industry trends, pharmaceutical business performance analysis, and potential implications for the industry.
Posted in Biotech, Global, Strategy | Also tagged , , , , | Leave a comment

Time for Russia to Get Serious about Biopharma

Back in 1980, the biotech industry did not exist. There was little difference between the means of production in Western markets and the socialist planned economies embodied by Russia – medicines, still a low-tech purchase, played a modest role in the delivery of health care in both sectors. What happened in the ensuing decades has […]
Posted in Biotech, Emerging Markets, Europe, Global, Strategy | Also tagged , , | 1 Comment

True Pharma Innovation Lies in Quality — not Quantity — of Approvals, say FDA analysts

We’re already embroiled in the annual speculation game about whether FDA approvals this year will keep pace with last year’s near-record of 39 new molecular entities (NMEs) brought to market. The tally is closely watched as a sign of the state of biopharmaceutical innovation and the health of the pharmaceutical industry and biomedical research enterprise.
Posted in Biotech, FDA, Regulatory | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta